Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients

Hematology Journal

Volumn 1, Issue 5, 2000, Pages 295-300

  Papassotiriou, Ioannis ^a   Voskaridou, Ersi ^b   Stamoulakatou, Alexandra ^a   Loukopoulos, Dimitris ^c,d  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Erythropoietin; Fetal hemoglobin; Hydroxyurea; Sickle cell disease

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN F; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BIOSYNTHESIS; BLOOD; DRUG EFFECT; ERYTHROID PRECURSOR CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY; LIVER; MALE; METABOLISM; MIDDLE AGED; SECRETION; SICKLE CELL ANEMIA; SICKLE CELL TRAIT; TIME;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; ERYTHROID PROGENITOR CELLS; ERYTHROPOIETIN; FEMALE; FETAL HEMOGLOBIN; GENE EXPRESSION REGULATION; HUMANS; HYDROXYUREA; KIDNEY; LIVER; MALE; MIDDLE AGED; SICKLE CELL TRAIT; TIME FACTORS;

EID: 0034584651     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200049     Document Type: Article

References (24)

1. Kranz S. Erythropoietin. Blood 78: 419, 1991.
2. Koury M, Bondurant M. The molecular mechanism of erythropoietin action. European Journal of Biochemistry 210: 649, 1992.
3. Sherwood JB, Goldwasser E, Chilcote R, Carmichael RD, Nagel RL. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 67: 46, 1986.
4. Scott J, Hillery C, Brown E, Misiewicz V, Labotka R. Hydroxyurea therapy in children severely affected with sickle cell disease. Journal of Pediatrics 128: 820, 1996.
5. Bunn F. Pathogenesis and treatment of sickle cell disease. New England Journal of Medicine 337: 762, 1997.
6. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR and the Investigators of the Multicenter study of hydroxyurea in sickle cell anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine 332: 1317, 1995.
7. Voskaridou V, Kalotychou V, Loukopoulos D. Clinical and Laboratory effects of long term administration of Hydroxyurea to patients with sickle cell/β-thalassemia. British Journal of Haematology 89: 479, 1995.
8. Prehu C, Ducrocq R, Godart C, Riou J, Galacteros F. Determination of HbF levels: the routine methods. Hemoglobin 22: 459, 1998.
9. Lindstedt G, Lundberg P-A. Are current methods for measurement of erythropoietin (EPO) in human plasma or serum adequate for the diagnosis of polycythaemia vera and the assessment of EPO deficiency? Scandinavian Journal of Clinical and Laboratory Investigation 58: 441, 1998.
10. Croizat H, Nagel R. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. American Journal of Hematology 60: 105, 1999.
11. Tancabelic J, Sheth S, Paik M, Piomelli S. Serum transferrin receptor as a marker of erythropoiesis suppression in patients on chronic transfusion. American Journal of Hematology 60: 121, 1999.
12. Birgegard G, Wide L, Simonson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. British Journal of Haematology 72: 462, 1989.
13. Piroso E, Erslev A, Caro J. Inappropriate increase in erythropoietin titers during chemotherapy. American Journal of Hematology 32: 248, 1989.
14. Shapira L, Antin J, Ransil B, Antman K, Eder JP, McGarigle C, Goldberg M. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76: 2354, 1990.
15. Sawabe Y, Kikuno K, Iseki T, Iida S, Tabata Y, Yonemitsu H. Changes in serum erythropoietin and the reticulocyte count during chemotherapy for leukemias. European Journal of Haematology 57: 384, 1996.
16. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati, Beguin Y. Red blood cell precursors mass as an independent determinant of serum erythropoietin level. Blood 91: 2139, 1998.
17. Al-Khatti A, Veith RW, Papayannopoulou Th, Fritsch EF, Goldwasser E, Stamatoyannopoulos G. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. New England Journal of Medicine 317: 415, 1987.
18. Leroy-Viard K, Royer-Fessard P, Beuzard Y. Improvement of mouse beta-thalassemia by recombinant human erythropoietin. Blood 78: 1596, 1991.
19. Nagel R, Vichinsky E, Shah M, Johnson R, Spadacino E, Fabry ME, Mangahas L, Abel R, Stamatoyannopoulos G. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double blind study. Blood 81: 9, 1993.
20. Nizli G, Kavakli K, Aydinok Y, Oztop S, Cetingul N, Basak N. Recombinant erythropoietin trial in children with transfusion dependent homozygous β-thalassemia. Acta Haematologica 98: 199, 1997.
21. Al-Khatti A, Papayannopoulou T, Knitter G, Fritsch EF, Stamatoyannopoulos G. Cooperative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea. Blood 72: 817, 1988.
22. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal hemoglobin response to hydroxyurea in sickle cell disease. New England Journal of Medicine 328: 73, 1993.
23. Blau A, Stamatoyannopoulos G. Evolving Therapies in Globin Gene Disorders, p 144 In: Lechner K and Gadner H (eds). Proceedings of the Educational Programme of the XII Meeting of the ISH (European and African Division) Vienna. Schattauer pub: Stuttgard, 1993.
24. Meletis J, Papavassiliou S, Yataganas X, Vavourakis S, Konstantopoulos K, Poziopoulos C, Samarkos M, Michali E, Dalekou M, Eliopoulos G, Loukopoulos D, Devergie A, Gluckman E. 'Fetal' erythropoiesis following bone marrow transplantation as estimated by the number of F-cells in the peripheral blood. Bone Marrow Transplantation 14: 737, 1994.